Replies to post #17550 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

Inasmuch as CW admits the earliest possible US launch for M923 is early 2020 (due to the timing of the ABBV-AMGN patent trial, which starts in late 2019), it probably doesn't matter when MNTA obtains interchangeable status, as long as it happens prior to the launch.